Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer
Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer
复制标题
DOI：
10.1093/carcin/bgab088
复制
发表时间：
2021-09-24
期刊：
影响因子：
4.7
通讯作者：
Nishizuka, Satoshi S.
中科院分区：
文献类型：
--
作者：
Fujisawa, Ryosuke;Iwaya, Takeshi;Nishizuka, Satoshi S.
我们研究了使用数字PCR（dPCR）测量的早期循环肿瘤DNA（ctDNA）变化是否可以预测食管鳞状细胞癌（ESCC）的后期化疗反应。我们比较了42例ESCC化疗期间ctDNA和肿瘤体积的动态变化。使用受试者工作特征曲线分析，通过初始化疗周期前后ctDNA（后/前ctDNA）的变异等位基因频率和总肿瘤体积（后/前体积）的比值来评估后期化疗反应预测的准确性。总阳性和阴性客观反应（OR）定义为>50或= 50%，总OR可通过后/前ctDNA预测，准确度较高;后/前ctDNA的AUC高于后/前体积（分别为0.85和0.76）。低post-pre-ctDNA患者（n = 18）的总生存率显著高于高post-pre-ctDNA患者（n = 20; P = 0.03）。在ESCC患者中，化疗的初始周期后的早期ctDNA变化可高准确性地预测后期对治疗的反应。
We investigated whether early circulating tumor DNA (ctDNA) changes, measured using digital PCR (dPCR), can predict later chemotherapy responses in esophageal squamous cell cancer (ESCC). We compared the dynamics of ctDNA and tumor volumes during chemotherapy in 42 ESCC. The accuracy of predictions of later chemotherapy responses was evaluated by the ratio of the variant allele frequency of ctDNA (post-/pre-ctDNA) and the total tumor volume (post-/pre-volume) before and after an initial chemotherapy cycle using a receiver-operating characteristic curve analysis. Total positive and negative objective responses (ORs) were defined as either >50 or = 50%, the total OR could be predicted by the post-/pre-ctDNA with high accuracy; the AUC by post-/pre-ctDNA was higher than that by post-/pre-volume (0.85 versus 0.76, respectively). Patients with low post-/pre-ctDNA (n = 18) had a significantly better overall survival rate than those with high post-/pre-ctDNA (n = 20; P = 0.03). Early ctDNA changes after an initial cycle of chemotherapy predict later responses to treatment with high accuracy in ESCC patients..